{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-248189","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2023-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.853295+00:00","generated_at":"2026-06-10T06:41:11.202076+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Repligen appoints Olivier Loeillot as President and CCO; Hunt remains CEO","bullets":["Loeillot appointed President and Chief Commercial Officer effective Oct 2, 2023; reports to CEO Tony Hunt.","Base salary $600k, target bonus 75% of base, signing bonus $1.35M, equity $4M vesting over 5 years.","Hunt relinquishes President role effective Oct 2 but remains CEO; Loeillot has 20+ yr bioprocess experience from Cytiva/GE and Lonza."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-248189","json":"https://secwatch.observer/filing/0001193125-23-248189.json","markdown":"https://secwatch.observer/filing/0001193125-23-248189.md","text":"https://secwatch.observer/filing/0001193125-23-248189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312523248189/0001193125-23-248189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312523248189/d463559d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:41:11.202076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09902c26c3","claim":"Tony Hunt changed role as President at REPLIGEN CORP.","evidence_excerpt":"In connection with Mr. Hunt’s and the rest of the Board’s appointment of Mr. Loeillot’s as President and Chief Commercial Officer, Mr. Hunt will relinquish his role of President, effective October 2, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/730272/000119312523248189/0001193125-23-248189-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"relinquish"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"b7d3ef33ed","claim":"Olivier Loeillot was appointed as President and Chief Commercial Officer at REPLIGEN CORP.","evidence_excerpt":"On October 2, 2023, Repligen Corporation (the “Company”) announced that Olivier Loeillot would be joining the Company as its President and Chief Commercial Officer, effective October 2, 2023 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/730272/000119312523248189/0001193125-23-248189-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}